Navigation Links
Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
Date:7/11/2012

SAN DIEGO, July 11, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for completion of enrollment of the Light Study, the Contrave® cardiovascular outcomes clinical trial. Orexigen now expects to complete enrollment of patients required for the interim analysis of the Light Study in the first quarter of 2013, potentially reducing by half the original projections.

"2012 has been a year of focused execution at Orexigen in order to conduct the Light Study as quickly as possible," said Michael Narachi, CEO of Orexigen. "The outstanding efforts of our team and our partners have resulted in enrollment rates of the targeted population that are much faster than originally expected."

The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo. After approximately 87 MACE have been adjudicated, Orexigen will conduct an interim analysis. Orexigen plans to resubmit the Contrave New Drug Application for approval if in the interim analysis the company is able to exclude a doubling of risk of MACE in patients receiving Contrave compared to placebo.

Orexigen is targeting to enroll a patient population with a 1.5% annualized background rate of MACE. The demographics (age, gender, smoking status, prevalence of cardiovascular disease, diabetes and other co-morbidities) of the patients enrolled into the study to date are in line with the targeted population and the projected MACE rate.

Since initiation of the Light Study at the beginning of June, over 1,500 patients have been enrolled into the study at approximately 100 sites that have been activated thus far. The remaining 200 sites are scheduled to be activated by the end of August. With the revised enrollment projections, and assumin
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
4. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
5. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
6. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
7. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
8. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
9. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
10. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
11. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 /PRNewswire/ ... that its shareholders have approved Mylan,s proposed acquisition ... TASE) and the related issuance of Mylan ordinary ... meeting of shareholders held today. The transaction received ... extraordinary general meeting. In addition, the transaction received ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES ... recently announced that it will be devoting an entire short segment to the subject ... people around the globe on a daily basis, but recent advancements in medical science ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time ... part with their subsidiary USPI Tenet Health. , The American Heart Association hosts their ... and stroke. They believe that together, a difference can be made. Walkers can participate ...
(Date:8/28/2015)... , ... August 28, 2015 , ... The 6th ... renowned Brain Aneurysm Foundation has added yet another accolade to its cadre of widespread ... , “With the help of the medical community and the University of ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3
... off from certain osteoporosis drugs may be beneficial to bone ... System. Researchers found that bone density remained stable for three ... a popular class of osteoporosis drugs that can cause fractures ... bone. "These drugs are potentially harmful when taken for ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, Nov. ... evidence that people infected with HIV, the virus that causes ... other patients when they undergo kidney transplants. Up until ... HIV patients because of fear that AIDS would quickly kill ...
... Johns Hopkins have identified a compound that could be ... The compound, called a glutaminase inhibitor, has been ... scientists say, may have the potential to be used ... Johns Hopkins scientists, are inventors on patent applications related ...
... NC Researchers have been stymied for years over the ... produce antibodies in response to the pathogen antibodies that ... at Duke University Medical Center can explain why: Some of ... can,t actually "see" the virus until after it,s already invaded ...
... THURSDAY, Nov. 18 (HealthDay News) -- Millions of harried ... indoor smoking at one in every four major U.S. ... smoke-free policies at large-hub airports in 2002 and 2010 ... nation,s largest airports, including three of the five busiest: ...
... Reinberg HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay ... example, new research finds that doctors, prescribing patterns vary across ... U.S. Food and Drug Administration. The result is ... depending on where they live, the researchers said. "We ...
Cached Medicine News:Health News:Taking a break from osteoporosis drugs can protect bones 2Health News:HIV Patients Do Well After Kidney Transplants: Study 2Health News:HIV Patients Do Well After Kidney Transplants: Study 3Health News:Compound that blocks sugar pathway slows cancer cell growth 2Health News:Compound that blocks sugar pathway slows cancer cell growth 3Health News:Why so many antibodies fail to protect against HIV infection 2Health News:Smoking Still Allowed at 1 in 4 Major U.S. Airports 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 2Health News:Despite FDA Warning, Avandia Use Varies Across U.S. 3
All purpose, low profile punches with a large square bite....
... With the OPMI Vario/NC33 System, Carl ... invasive spine market. , ,The success ... solely attributable to its extremely compact and ... by the first graphical touchscreen to be ...
... uniquely combines solutions for basic requirements ... intra-operative diagnostics, integration of the entire ... surgical microscope into the hospital's information ... for OR staff.,OPMI Pentero is the ...
Osteoprep instruments provide an array of bone shaping devices especially suited for notchplasties....
Medicine Products: